Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems

Area of Science:

• Psychiatry
• Neuroscience
• Addiction Medicine

Background:

• Alcohol use disorder (AUD) is a significant public health concern with severe individual and societal impacts.
• Ketamine-assisted therapy shows promise for AUD, but its mechanisms of action require further elucidation.
• Understanding how pharmacological agents interact with behavioral therapies is crucial for optimizing addiction treatment.

Purpose of the Study:

• To investigate the efficacy of esketamine combined with mindfulness-based intervention (MBI) for individuals with alcohol misuse.
• To determine if esketamine enhances engagement in MBI for AUD patients.
• To assess the impact of enhanced MBI engagement on alcohol-related outcomes.

Main Methods:

• A double-blind, pilot study involving 28 participants with alcohol problems.
• Random assignment to receive sublingual esketamine hydrochloride or a placebo (vitamin C oral thin film).
• Two weeks of daily MBI, with assessments of mindfulness, MBI engagement, alcohol cravings, and consumption.

Main Results:

• Esketamine significantly increased psychological engagement with daily MBI compared to placebo.
• Participants receiving esketamine experienced transient reductions in alcohol cravings.
• Esketamine administration was associated with significantly greater mystical and dissociative experiences.

Conclusions:

• Esketamine may enhance treatment outcomes for AUD when integrated with mindfulness-based therapies.
• Increased engagement with meditative practices appears to be a key mechanism through which esketamine exerts its effects.
• Further research is warranted to explore the therapeutic potential of esketamine in addiction treatment.